Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2023)
Recursion Pharmaceuticals' (RXRX) quarterly Receivables came in at $11.1 million in Q3 2023, down 4.91% YoY from $11.6 million in Q3 2022, and up 8.99% on a QoQ basis from $10.2 million in Q2 2023.
Recursion Pharmaceuticals (RXRX) Receivables (2020 - 2023) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 4 years of Receivables data on file, last reported at $11.1 million in Q3 2023.
- Quarterly Receivables fell 4.91% year-over-year to $11.1 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $11.1 million (down 4.91% YoY) and the FY2022 annual result came in at $2.8 million, down 69.71% from the prior year.
- Receivables climbed to $11.1 million in Q3 2023, from $10.2 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $11.7 million in Q2 2022 to a low of $49000.0 in Q2 2021.
- A 4-year average of $6.4 million and a median of $9.1 million in 2021 frame the typical range for Receivables.
- The widest YoY moves for Receivables: up 23736.73% in 2022, down 69.71% in 2022.
- Tracing RXRX's Receivables over 4 years: stood at $156000.0 in 2020, then soared by 5726.92% to $9.1 million in 2021, then sank by 69.71% to $2.8 million in 2022, then soared by 301.89% to $11.1 million in 2023.
- The last three Receivables figures came in at $11.1 million (Q3 2023), $10.2 million (Q2 2023), and $2.8 million (Q4 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 11.06 Mn |
| Jun 30, 2023 | 10.15 Mn |
| Dec 31, 2022 | 2.75 Mn |
| Sep 30, 2022 | 11.64 Mn |
| Jun 30, 2022 | 11.68 Mn |
| Mar 31, 2022 | 11.40 Mn |
| Dec 31, 2021 | 9.09 Mn |
| Sep 30, 2021 | 2.28 Mn |
| Jun 30, 2021 | 49,000.00 |
| Mar 31, 2021 | 71,000.00 |
| Dec 31, 2020 | 156,000.00 |